Marker Therapeutics, Inc. — Director's Dealing 2018

Dec 28, 2018

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Marker Therapeutics, Inc. (MRKR)
CIK: 0001094038
Period of Report: 2018-12-21

Reporting Person: Hoang Tsvetelina P (VP, Research and Development)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	179711	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$9.18	2028-10-19	Common Stock (200000)		Direct
Employee Stock Option (Right to Buy)	$9.18	2028-10-19	Common Stock (1359855)		Indirect

Footnotes

F1: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended for service as the Company's Vice President, Research and Development. One quarter of the shares vest on the first anniversary of the grant date, the remainder of the shares vest in monthly installments over a three year period upon the continued employment of the Reporting Person by the Company through the vesting dates. The option exercise price is the closing price on the date of the grant, October 19, 2018.

F2: Represents options granted under the Company's 2014 Omnibus Stock Ownership Plan, as amended to Peter Hoang, Dr. Hoang's husband serves as the Company's Chief Executive Officer and President. The options vested and were exercisable immediately. The option exercise price is the closing price on the date of the grant, October 19, 2018.